2 days ago · New York
FTC: ‘Pharma bro’ Shkreli violated lifetime industry ban, should be held in contempt
What's happening
SignalsMonitor is following this as a markets story. Ars Technica and The Hill are the outlets attached to this story. The reports are tied to New York. The first report grouped here was at 13 Oct 2026, 17:05 UTC. 2 material updates are listed in the timeline. The headline in use is “FTC: ‘Pharma bro’ Shkreli violated lifetime industry ban, should be held in contempt”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
The Federal Trade Commission (FTC) and a coalition of seven states asked a federal court on Tuesday to punish Martin Shkreli for “flagrantly and repeatedly” violating a lifetime ban from being involved in the pharmaceutical industry. In a court filing in the U.
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by The Hill
FTC: ‘Pharma bro’ Shkreli violated lifetime industry ban, should be held in contempt
- Picked up by Ars Technica
Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says
Same story, different outlets
2 headlinesEach line is that outlet's headline. The article stays on the publisher's site.